| |  Online-Ressource |
|---|
| Verfasst von: | Mamlins, Eduards [VerfasserIn]  |
|---|
| | Scharbert, Lara [VerfasserIn] |
|---|
| | Cardinale, Jens [VerfasserIn] |
|---|
| | Krotov, Maria [VerfasserIn] |
|---|
| | Winter, Erik [VerfasserIn] |
|---|
| | Rathke, Hendrik [VerfasserIn] |
|---|
| | Strodel, Birgit [VerfasserIn] |
|---|
| | Ankrah, Alfred O. [VerfasserIn] |
|---|
| | Sathekge, Mike [VerfasserIn] |
|---|
| | Haberkorn, Uwe [VerfasserIn] |
|---|
| | Kratochwil, Clemens [VerfasserIn] |
|---|
| | Giesel, Frederik L. [VerfasserIn] |
|---|
| Titel: | The theranostic optimization of PSMA-GCK01 does not compromise the imaging characteristics of [99mTc]Tc-PSMA-GCK01 compared to dedicated diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in prostate cancer |
|---|
| Verf.angabe: | Eduards Mamlins, Lara Scharbert, Jens Cardinale, Maria Krotov, Erik Winter, Hendrik Rathke, Birgit Strodel, Alfred O. Ankrah, Mike Sathekge, Uwe Haberkorn, Clemens Kratochwil, Frederik L. Giesel |
|---|
| E-Jahr: | 2023 |
|---|
| Jahr: | 08 December 2023 |
|---|
| Umfang: | 9 S. |
|---|
| Fussnoten: | Gesehen am 30.01.2024 |
|---|
| Titel Quelle: | Enthalten in: Molecular imaging & biology |
|---|
| Ort Quelle: | Cham : Springer Nature Switzerland, 2002 |
|---|
| Jahr Quelle: | 2023 |
|---|
| Band/Heft Quelle: | (2023), Seite 1-9 |
|---|
| ISSN Quelle: | 1860-2002 |
|---|
| Abstract: | Radiolabeled PSMA-ligands play a major role in today’s nuclear medicine. Since approval of [177Lu]Lu-PSMA-617 for therapy of metastatic prostate cancer, availability of 177Lu became bottleneck of supply due to the high demand. Recently, a theranostic PSMA-ligand, PSMA-GCK01, was developed which can be labeled either diagnostically with 99mTc or therapeutically with 188Re with both nuclides available from well-known generator systems. This novel tracer might aid to overcome aforementioned supply limitations. In this investigation, the biodistribution and general imaging characteristics of [99mTc]Tc-PSMA-GCK01 were compared with the diagnostic reference compound [99mTc]Tc-EDDA/HYNIC-iPSMA in patients with advanced stage prostate cancer. In addition, the binding of both ligands to PSMA was analyzed at the molecular level using molecular docking. |
|---|
| DOI: | doi:10.1007/s11307-023-01881-y |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.1007/s11307-023-01881-y |
|---|
| | kostenfrei: Volltext: https://link.springer.com/article/10.1007/s11307-023-01881-y |
|---|
| | DOI: https://doi.org/10.1007/s11307-023-01881-y |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Prostate cancer |
|---|
| | PSMA-GCK01 |
|---|
| | SPECT |
|---|
| | Technetium-99 m |
|---|
| | Theranostic |
|---|
| K10plus-PPN: | 187952726X |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
¬The¬ theranostic optimization of PSMA-GCK01 does not compromise the imaging characteristics of [99mTc]Tc-PSMA-GCK01 compared to dedicated diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in prostate cancer / Mamlins, Eduards [VerfasserIn]; 08 December 2023 (Online-Ressource)
